EPS of ($0.04) beat estimates of ($0.0604) and revenues of $32.58M beat estimates of $32.49M. SaaS subscription revenue was at the high end of guidance and its operating loss was reduced by 38% year-over-year. It reported strong cash from operations of $4.6M, and it announced a share buyback plan of $50M. It is seeing strong growth of its GenAI pipeline and high win rates, it is taking longer for pipeline and SaaS growth for the second half of FY2025. We feel it is positioned decently well in the space, but we would not consider it a need-to-own stock.
5i Research Answer: